ArticleDiscover oncology2025
Investigating laryngeal squamous cell carcinoma: clinical features and the role of TAS2R16 polymorphisms and its protein levels.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLaryngeal squamous cell carcinoma (LSCC) is the second most common malignancy of the respiratory tract after lung cancer, presents symptoms like hoarseness, sore throat, and dysphagia, and about 150,000 new cases are diagnosed worldwide annually. Risk factors such as tobacco smoking, alcohol consumption, and genetic variations, including TAS2R16 polymorphisms, significantly influence LSCC development. Recent research suggests TAS2R16, a bitter taste receptor, may play a role in inflammation regulation and could be linked to cancer susceptibility, particularly in individuals with alcohol and nicotine dependency.
methodsA total of 312 LSCC patients and 320 healthy controls participated in the study. Deoxyribonucleic acid (DNA) was extracted using salting-out technology. Real time polymerase chain reaction was used for genotyping. Using the ELISA technique, serum levels were measured.
resultsThe distribution of TT, CT, and CC genotypes of TAS2R16 rs860170 is statistically significantly different in groups: LSCC patients, both early-stage and late-stage LSCC patients, patients without metastasis and control group. Results showed that TAS2R16 rs1357949 GG and AG genotypes together are associated with decreased odds of developing LSCC in non-smoking patients under the dominant model. Also, each rs1357949 G allele was found to decrease the odds of LSCC occurrence in non-smokers under the additive model. TAS2R16 serum levels in the LSCC were greater in TAS2R16 rs978739 CT genotype carriers than in the control group.
conclusionsThe distribution of TAS2R16 rs860170 genotypes varies notably between LSCC patients, including those at early and late stages, as well as those without metastasis. Additionally, rs1357949 GG and AG genotypes show a protective effect against LSCC development in non-smokers, with the G allele reducing the odds of occurrence. Higher serum levels of TAS2R16 were observed in LSCC patients with the rs978739 CT genotype, suggesting a potential link between these genetic variations and LSCC pathophysiology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.